Abbott Laboratories
ABT
$135.08
-$2.63-1.91%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 460.69% | 26.42% | 6.29% | -23.15% | 11.00% |
| Total Depreciation and Amortization | 0.75% | -0.50% | 0.00% | -0.98% | -1.33% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 406.84% | -17.02% | -53.62% | 26.67% | 105.13% |
| Change in Net Operating Assets | -5,604.26% | 148.96% | 78.00% | -434.78% | 178.20% |
| Cash from Operations | 6.03% | 38.01% | 91.22% | -66.26% | 61.85% |
| Capital Expenditure | -29.50% | -4.32% | -33.92% | 47.28% | -34.82% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | 100.00% |
| Divestitures | -- | -100.00% | -- | -- | -- |
| Other Investing Activities | -284.21% | -148.10% | 392.59% | 60.87% | -200.00% |
| Cash from Investing | -45.79% | -31.13% | -6.59% | 48.42% | -29.97% |
| Total Debt Issued | 0.00% | -99.55% | -- | -- | -- |
| Total Debt Repaid | -1,561.90% | 168.85% | 51.97% | 86.78% | 36.19% |
| Issuance of Common Stock | -72.83% | 607.69% | -90.30% | 294.12% | -39.29% |
| Repurchase of Common Stock | 58.06% | -24,933.33% | 98.67% | 12.74% | -12,850.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | 0.21% | 0.10% | -0.42% | -7.77% | 0.00% |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -18.08% | -99.24% | 32.74% | 42.69% | 12.31% |
| Foreign Exchange rate Adjustments | -330.56% | 376.92% | 63.89% | -244.00% | 186.21% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -89.84% | -18.78% | 214.87% | -427.27% | 116.61% |
